计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| R646891-2mg |
2mg |
期货 ![]() |
| |
| R646891-5mg |
5mg |
期货 ![]() |
| |
| R646891-10mg |
10mg |
期货 ![]() |
| |
| R646891-50mg |
50mg |
期货 ![]() |
| |
| R646891-100mg |
100mg |
期货 ![]() |
|
| 别名 | 盐酸雷沙三嗪 |
|---|---|
| 英文别名 | CNV1014802 hydrochloride | CNV-1014802 hydrochloride | (2S,5R)-5-(4-(2-fluorobenzyloxy)phenyl)pyrrolidine-2-carboxamide hydrochloride | DTXSID80458106 | (5R)-5-(4-[2-fluorobenzyloxy]phenyl)-L-prolinamide hydrochloride | (5R)-5-(4-{[(2-Fluorophenyl)methyl] |
| 规格或纯度 | ≥99% |
| 英文名称 | Raxatrigine hydrochloride |
| 生化机理 | 盐酸雷沙曲金(GSK-1014802 盐酸盐)是一种新型小分子状态依赖性钠通道阻滞剂;Nav1.7 钠通道抑制剂。 |
| 储存温度 | 2-8°C储存,干燥 |
| 运输条件 | 冰袋运输 |
| 产品介绍 |
Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor . In Vitro Like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. Raxatrigine (GSK-1014802) received orphan-drug designation from the US Food and Drug Administration in July 2013. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Sodium channel blocker |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | (2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide;hydrochloride |
| INCHI | 1S/C18H19FN2O2.ClH/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22;/h1-8,16-17,21H,9-11H2,(H2,20,22);1H/t16-,17+;/m1./s1 |
| InChi Key | HEPUBAGOKRIZEO-PPPUBMIESA-N |
| Smiles | C1CC(NC1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N.Cl |
| Isomeric SMILES | C1C[C@H](N[C@H]1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N.Cl |
| PubChem CID | 16046067 |
| 分子量 | 350.8 |
| 溶解性 | DMSO : ≥ 31 mg/mL (88.36 mM) H2O : 14.29 mg/mL (40.73 mM; Need ultrasonic) |
|---|---|
| 分子量 | 350.800 g/mol |
| XLogP3 | |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 350.12 Da |
| 单同位素质量Monoisotopic Mass | 350.12 Da |
| 拓扑极表面积Topological Polar Surface Area | 64.400 Ų |
| 重原子数Heavy Atom Count | 24 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 398.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 2 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P271: 仅在室外或通风良好的地方使用。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P321: 特殊处理(请参阅此标签上的...)。 P330: 漱口 P302+P352: 如皮肤沾染:用水充分清洗。 P304+P340: 如误吸入:将人转移到空气新鲜处,保持呼吸舒适体位。 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 P362+P364: 脱掉沾污的衣服,清洗后方可重新使用。 P405: 密闭存放 P403+P233: 存放在通风良好的地方。保持容器密闭。 P501: 将内容物/容器处理到。。。 P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。 P301+P317: 如果被吞咽:请寻求医疗帮助。 P337+P317: 如果眼睛刺激持续:寻求医疗帮助。 P332+P317: 如果出现皮肤刺激:请寻求医疗帮助。 P319: 如果你感到不适,请寻求医疗帮助。 |